|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:carboplatin
|
|
gptkbp:activities
|
gptkb:weapon
|
|
gptkbp:advises
|
as directed by physician
|
|
gptkbp:appointed_by
|
intravenous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Paraplatin
gptkb:carboplatin
Paraplatin-A
|
|
gptkbp:clinical_trial
|
Phase II
combination therapy
Phase III
monotherapy
|
|
gptkbp:contraindication
|
severe allergic reactions
kidney problems
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:frequency
|
every 3-4 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Paraplatin
|
|
gptkbp:indication
|
gptkb:healthcare_organization
ovarian cancer
|
|
gptkbp:ingredients
|
gptkb:carboplatin
C6 H10 N4 O4
|
|
gptkbp:interacts_with
|
antibiotics
anticoagulants
other chemotherapy drugs
|
|
gptkbp:invention
|
2025
patented
|
|
gptkbp:is_monitored_by
|
blood tests
kidney function
liver function
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:lifespan
|
3-6 hours
|
|
gptkbp:manager
|
IV
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:previous_name
|
gptkb:carboplatin
|
|
gptkbp:research
|
improves survival rates
effective in recurrent ovarian cancer
less toxic than cisplatin
used in elderly patients.
used in pediatric oncology
|
|
gptkbp:research_areas
|
oncology
pharmacology
clinical research
|
|
gptkbp:safety_features
|
Category D
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
allergic reactions
vomiting
hearing loss
thrombocytopenia
neuropathy
neutropenia
low blood cell counts
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:water_management
|
hazardous waste
|
|
gptkbp:weight
|
371.25 g/mol
|